Sign in Subscribe

Topic

news

A collection of 3 issues

M&A: Week 12

In this week's M&A review * 2Seventybio to be acquired by Bristol Myers Squibb for US$286 million in cash deal 2Seventybio to be acquired by Bristol Myers Squibb for US$286 million in cash deal 2Seventybio has announced a definitive merger agreement under which Bristol Myers

M&A: Week 11

In this week's M&A review * Jazz Pharmaceuticals acquires Chimerix for approximately US$935 million in cash Jazz Pharmaceuticals acquires Chimerix for approximately US$935 million in cash Through the acquisition Jazz Pharmaceuticals gains access to dordaviprone, a novel small molecule therapy in development for H3 K27M-mutant

M&A: Week 10

In this week's M&A review * Bluebird bio to be acquired by Carlyle and SK Capital Bluebird bio to be acquired by Carlyle and SK Capital According to report the company has been acquired for about US$30 million. Carlyle and SK Capital will provide primary capital